The Vanguard Group Discloses Stake in Avadel Pharmaceuticals

The Vanguard Group, Inc. has submitted a Form 8.3 disclosure concerning Avadel Pharmaceuticals plc. This disclosure is part of the requirements set by the Irish Takeover Panel under Rule 8.3 of the 1997 Takeover Panel Act. As of January 8, 2026, Vanguard holds 5,869,355 ordinary shares of Avadel, representing 6.03% of the company's shares.

The document details Vanguard's interests and short positions in Avadel's ordinary shares, alongside recent transactions involving these securities. Specifically, the company purchased 4,233 shares and sold 285 shares, all at a price of USD 21.48 per share. No cash or stock-settled derivatives or agreements to purchase or sell were disclosed beyond these outright share transactions.

The filing also clarifies that Vanguard has no indemnity, option arrangements, or understandings related to Avadel's securities